Patents by Inventor Toby K. Eisenstein

Toby K. Eisenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cannabinoid receptor treatments
    Patent number: 9855225
    Abstract: The present invention includes methods and compositions for treating a transplant recipient by administration of a CB2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: January 2, 2018
    Assignee: TEMPLE UNIVERSITY OFFICE OF TECHNOLOGY TRANSFER
    Inventors: Toby K. Eisenstein, Rebecca R. Hartzell, Martin W. Alder, Joseph J. Meissier
  • CANNABINOID RECEPTOR TREATMENTS
    Publication number: 20170014355
    Abstract: The present invention includes methods and compositions for treating a transplant recipient by administration of a CB2 receptor agonist either alone or in combination with one or more active pharmaceutical ingredients to block the rejection of foreign tissue and prolong grafted organs, tissues and cells.
    Type: Application
    Filed: August 17, 2012
    Publication date: January 19, 2017
    Inventors: Toby K. EISENSTEIN, Rebecca R. HARTZELL, Martin W. ALDER, Joseph J. MEISSIER
  • Group B Streptococcus antigens and vaccines
    Patent number: 4439422
    Abstract: Pure Group B Streptococcus antigen and Group B, Type III Streptococcus antigen are isolated, separated and purified from the culture medium in which the Group B, Type III Streptococcus are grown. The process involves (a) culturing the Group B, Type III Streptococcus in a nutrient medium, free of animal proteins and lipids, containing from 1 to 5% by weight glucose and from 0.04 M to 0.16 M phosphates; (b) separating the bacterial cells from the culture medium; (c) extracting and separating the Group B antigens and the Type III antigens from the culture medium supernatant by means of an anion exchanger; and, (d) purifying the resulting antigenic materials by chromatography on an agarose gel column. The antigens can be used as vaccines against infections caused by Group B or Group B, Type III Streptococcus.
    Type: Grant
    Filed: February 2, 1982
    Date of Patent: March 27, 1984
    Assignee: Research Corporation
    Inventors: Robert M. Swenson, Gerald D. Shockman, Toby K. Eisenstein, Roberta B. Carey